arrow
M

Mireia Margelí Vila

institut català d’oncologia (ico)-badalona (hospital germans trias i pujol)
H指数:31
被引数:3,602

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+/HER2− metastatic breast cancer: a translational analysis of the GEICAM/2013-02 PEARL trial

动态胸苷激酶活性独立捕获治疗特异性的生物学反应,并与内分泌耐药的HR+/HER2−转移性乳腺癌的结局独立相关:GEICAM/2013-02 PEARL试验的转化分析

2026-05-250
OAAI
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: the PHENOMENAL phase 2 study

脂质体伊立替康在HER2阴性乳腺癌和脑转移患者中的应用:PHENOMENAL II期研究

2025-12-040
PRE
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

免疫相关转录组特征可预测HR+/HER2–乳腺癌中CDK4/6抑制剂的疗效

2025-08-070
OA
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Catala d'Oncologia Breast Cancer Observational Cohort Study

综合临床特征分析及长期随访:Institut Catala d'Oncologia乳腺癌观察性队列研究

CANCERS
IF4.4
2025-04-190
OA
Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?

评估真实世界数据中乳腺癌患者口服内分泌治疗依从性的质量:真实世界数据有多真实?

CANCERS
IF4.4
2025-01-090
OA
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
2024-10-230
OAAI
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
2024-07-111
OAAI
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib plus endocrine therapy in HR+/HER2-metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial
2024-05-020
PRE
Real-world features and outcomes of young advanced breast cancer (ABC) patients (pts) from RegistEM (GEICAM/2014-03) study
2024-05-020
PRE
SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
2024-05-020
PRE
Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial
2024-05-020
PRE
Enhancing Informative Outcomes with Liquid Biopsy in a Real-World Population of Patients with Advanced Breast Cancer: Analysis of the SOLTI-1903 HOPE Study
2024-05-020
PRE
Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor- positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024-05-020
PRE
First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer

SOLTI-1903希望以患者为中心的晚期乳腺癌分子筛查计划的第一个结果

2023-10-010
OAAI
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer
2023-09-042
OAAI
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study
2023-08-0116
PRE
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

HOPE (SOLTI-1903) 乳腺癌研究: 以患者为中心的真实世界临床实践研究,评估基因组数据对局部晚期或转移性乳腺癌患者下一步治疗决策选择的影响

2023-04-281
OAAI
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
2023-03-0123
OAAI